LEO Pharma announces US regulatory submission of the first aerosol foam for psoriasis

11:31 EST 6 Jan 2015 | BioPortfolio

Ballerup, Denmark: LEO Pharma announced it has submitted a New Drug Application to the US Food and Drug Administration (FDA) for calcipotriene/betamethasone dipropionate aerosol foam 0,005%/0,064% for the treatment of psoriasis vulgaris.

The novel aerosol foam formulation of the fixed combination calcipotriene/betamethasone dipropionate has been developed with the aim of improving treatment for patients with psoriasis vulgaris1,2 – the most common clinical form of psoriasis.3

The regulatory submission in the US is based on studies of patients with psoriasis vulgaris. These include the Phase 3a PSO-FAST study which evaluated efficacy, safety, itch relief and itch-related sleep loss across a four week period,4 and the Phase 2 MUSE safety study.5
Kim Kjøller, Senior Vice President, Global Development, commented:

“Psoriasis is a chronic, debilitating disease. Patients with inadequately managed psoriasis can experience substantial burden of illness, with similar reductions in quality of life to those experienced by patients with diabetes or cancer.5 With the regulatory submission announced today, we are taking a step further in our mission towards reducing this burden by making calcipotriene/betamethasone dipropionate aerosol foam available for people living with psoriasis.”

Regulatory filings in Europe and other countries are planned during the course of 2015 and 2016.

With this latest submission LEO Pharma reinforces a strong commitment to dermatology.

About Psoriasis

Psoriasis is a chronic, inflammatory disease, which is frequently accompanied by multiple physical and/or psychological comorbidities, such as metabolic syndrome and psoriatic arthritis.

Psoriasis is estimated to affect about 2-4% of the population in western countries.6 80% of patients are affected by psoriasis vulgaris – the most common clinical form of psoriasis.

Topical treatments are first-line therapies for the majority of patients since approximately 80% of the patients have mild or moderate psoriasis.

About LEO Pharma

Founded in 1908, LEO Pharma is an independent, research-based pharmaceutical company. LEO Pharma develops, manufactures and markets pharmaceutical drugs to dermatologic and thrombotic patients in more than 100 countries globally. The company has its own sales forces in 61 countries and employs around 4,800 people worldwide. LEO Pharma is headquartered in Denmark and is wholly owned by the LEO Foundation.

For more information visit
Subscribe to our YouTube channel:  
Follow us on Twitter:

Global Media Contact Polly Lutter Senior Global Communications Manager LEO Pharma A/S, Denmark Tel: +45 41 37 12 27 Tony Jackson Burson-Marsteller, London Tel: +44 207 400 6370 NEXT ARTICLE

More From BioPortfolio on "LEO Pharma announces US regulatory submission of the first aerosol foam for psoriasis "

Quick Search


Relevant Topics

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Alzumab (Itolizumab)
Biocon Launches ALZUMAb™ - a ‘First in Class’ Novel Biologic Treatment for Psoriasis Patients in India • ALZUMAb™-World's first novel anti-CD6 antibody developed by Biocon to address a large unmet need for th...